A
Alcista
Alcista · 25%JNJ
$189.23
Precio del escenario
$263.810
-3.746 (-1.42%)Al cierre
Loading chart…
- Máximo
- 266.025
- Apertura
- 265.820
- Precio medio ponderado por volumen
- 264.08
- Volumen
- 5.31M
- Capitalización
- —
- Mínimo
- 262.400
- Importe
- 1.40B
- EV/EBITDA, TTM
- 19.16
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. It is also focused on proprietary Firelink degrader antibody conjugate platform.
Análisis de IA of Johnson & Johnson (JNJ)
ComprarJohnson & Johnson is a good buy right now, as it is currently priced at $263.81, with a forward P/E ratio of 21.01 indicating reasonable valuation for future earnings growth. The stock has shown a year-to-date change of +27.23%, reflecting strong performance in a challenging market. However, the main risk is the insider selling activity, which has increased by 159.20% over the last month, indicating potential concerns from insiders about future performance.
Recomendaciones de analistas (23)
-17.18% Potencial de caída
Comprar
12 Comprar
8 Mantener
3 Vender
Actual: 263.81
Mínimo
190.00
Promedio
218.50
Máximo
240.00
BofA
Neutral
$282
2026-10-09
BofA
2026-10-09
Precio objetivo
$282
Neutral
RBC Capital
Superar al mercado
$290
2026-10-06
RBC Capital
2026-10-06
Precio objetivo
$290
Superar al mercado
Citi
Comprar
$303
2026-10-05
Citi
2026-10-05
Precio objetivo
$303
Comprar
JPMorgan
Neutral
$285
2026-09-29
JPMorgan
2026-09-29
Precio objetivo
$285
Neutral
BofA
Neutral
$278
2026-09-29
BofA
2026-09-29
Precio objetivo
$278
Neutral
Métricas de valoración
El PER previsto actual de Johnson & Johnson (JNJ) es 21.01, frente a su media de 5 años de 16.56.
Escenarios de precio de Alphio AI para JNJ
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con JNJ en cartera
Cronología de eventos
Noticias
- 6.510-24Fool
Comparing Investment Paths of Amgen and Johnson & Johnson
4.510-24CNBCWall Street Volatility Driven by AI Financing Concerns
2.010-24PRnewswireNew Advances in Prostate Cancer Treatment with Apalutamide
2.010-24NewsfilterApalutamide Plus ADT Significantly Reduces Recurrence Risk in Prostate Cancer
4.510-23CNBCMarket Volatility and Investment Strategy Recap
Preguntas frecuentes sobre JNJ, respondidas por Alphio AI
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. It is also focused on proprietary Firelink degrader antibody conjugate platform. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Johnson & Johnson is a good buy right now, as it is currently priced at $263.81, with a forward P/E ratio of 21.01 indicating reasonable valuation for future earnings growth. The stock has shown a year-to-date change of +27.23%, reflecting strong performance in a challenging market. However, the main risk is the insider selling activity, which has increased by 159.20% over the last month, indicating potential concerns from insiders about future performance.
23 analysts cover JNJ: 12 rate it Buy, 8 Hold and 3 Sell. The average price target is 218.50.
Comunidad
Más ↗
$JNJ #ESMO Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026. The first readout following the acquisition of the RIPTAC™ platform shows promising anti-tumor activity with JNJ-6143, a novel oral investigational molecule, in difficult-to-treat prostate cancer. It offers a completely new way of thinking about cancer therapy.
Mostrar más
$PEP Pepsi had an ugly support break today and is on its way to fill the gap from July 2025 next ($128.82) 🥤 - Now down more than 22% from the February highs - Just elected the $JNJ CEO to its board
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.